Clinical Trial: STA-5326 in Crohn's Disease Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450

Brief Summary: The purpose of this study is to determine the safety and tolerability of STA-5326 given once daily or twice daily to Crohn's Disease patients with moderate disease.

Detailed Summary:
Sponsor: Synta Pharmaceuticals Corp.

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Synta Pharmaceuticals Corp.

Dates:
Date Received: July 19, 2004
Date Started: February 2004
Date Completion: November 2004
Last Updated: June 23, 2005
Last Verified: May 2005